48 results about "Diabetic retinopathy" patented technology

The present invention relates to a protein tyrosine kinase inhibitor for the treatment of protein tyrosine kinase-mediated proliferative diseases or symptoms, for example ocular diseases including pathological neovascularization, retinal ischemia, retinal edema, and diabetic retinopathy, as well as malignant tumors. More particularly, the present invention relates to a compound with protein tyrosine kinase inhibitory activity and / or improved solubility and ocular bioavailability, and its uses in the treatment of ocular diseases and malignant tumors.

This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and / or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

The present disclosure relates to methods and systems for quantifying the vascular pattern using ocular imaging that shows vessel profiles for the detection, prevention, and treatment of diabetic retinopathy and other related ocular vascular diseases.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

The present application relates to the technical field of biological medicine, and particularly relates to application of Crybb2 recombinant protein in treatment and / or prevention of diabetic retinopathy. The present application finds that the use of Crybb2 recombinant protein can improve the activity of müller cells, reduce the level of GFAP, restore the level of GS, reduce inflammation, reduce apoptosis of retinal cells and restore the structure and function of the retina. It can be used for treatment and / or prevention of diabetic retinopathy.

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

The invention relates to the technical field of biological medicine, in particular to application of Crybb2 recombinant protein to treatment and / or prevention of diabetic retinopathy. The application finds that by using the Crybb2 recombinant protein, the muler cell activity can be improved, the GFAP level can be reduced, the GS level can be recovered, the inflammation can be alleviated, the apoptosis of retinal cells can be reduced, and the structure and function of the retina can be recovered. The compound can be used for treating and / or preventing diabetic retinopathy.

The present invention relates to usage of hydrogen peroxide compounds as active substance in elimination of diabetic retinopathy diseases and the symptoms resulting from these diseases, and pharmaceutical compositions comprising hydrogen peroxide as active substance in the treatment of said diseases.

The present application belongs to the field of biomedicine. Disclosed are an siRNA for inhibiting KRAS gene expression, and a modified form thereof and the use thereof. Provided in the present application is a double-stranded RNA molecule targeting KRAS, wherein the molecule can treat KRAS-associated diseases such as metastatic non-small cell lung cancer, metastatic pancreatic ductal adenocarcinoma, KRAS G12C+ non-small cell lung cancer, diabetic retinopathy, leukemia, cholangiocarcinoma, metastatic colorectal cancer, gastric cancer, advanced non-small cell lung cancer, stage-IV non-small cell lung cancer, gastric adenocarcinoma, sepsis, KRAS G12C-mutated advanced non-small cell lung cancer and gallbladder cancer.

The invention discloses a diabetic retinopathy segmentation method based on multiple branches and visual Mangbar, and relates to the field of medical image processing. The problems that small target lesions are difficult to accurately segment, the model is complex, the modeling ability of global context information is insufficient and the like still exist in the aspect of diabetic retinopathy in the prior art are solved. The invention provides a diabetic retinopathy segmentation model, which takes a color eye fundus image as input data, extracts multi-scale information through a multi-branch-based multi-scale attention fusion module MSAF Block, and obtains effective context information by using MSMFB of different scales. And meanwhile, a joint weighted jump module is constructed through a shared attention jump connection module to effectively fuse multi-level features, and finally, a final segmentation result is output through a lightweight decoder. Through the model, efficient segmentation of four lesions can be realized. The method is also suitable for the field of diabetic retinopathy image processing.

MEDICAL DEVICE FOR EARLY STAGE DETECTION OF DIABETIC RETINOPATHY

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, cardiomyopathy, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, galactosemia, asthma, PMM2-CDG and the like.

Ocular diseases can create significant impacts on quality of life and a substantial societal economic burden. For example, diabetic retinopathy is a significant cause of blindness in the adult population. Despite the prevalence of ocular disease, the treatment of many ocular diseases lack effective pharmaceutical treatment. In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to method for treating or preventing an ocular disease in a subject. The methods involve administering one or more compounds as described herein.

The application discloses a self-attention segmentation method for diabetic retinopathy fundus images, and comprises the following steps: S1, collecting diabetic retinopathy fundus images, and obtaining a first feature map set after pretreatment; S2, inputting the first feature map set into a swin-transformer network to obtain a third feature map set; and S3, inputting the third feature map set into a prediction layer network to obtain a prediction image, and completing the self-attention segmentation of the diabetic retinopathy fundus images. The application can perform fine segmentation on high-resolution images, and has better effect than traditional U-Net architecture, M-Net, Swin-Unet architecture and the like. Global information can be acquired more. The application uses patch to perform picture cutting and then performs picture prediction, so that the neural network size can be effectively reduced, and the neural network training speed can be accelerated.

A method is provided for treating a patient having a neovascular ocular disease.

The present invention relates to an ulva australis extract with antioxidant activity and cell proliferation activity for use as a drug to prevent and / or treat neurodegenerative diseases of the retina, especially those associated with oxidative stress or loss of photoreceptors, such as age-related macular degeneration, glaucoma, inherited retinal dystrophies, diabetic retinopathy and retinitis pigmentosa.

The application provides a diabetic retinopathy diagnosis and treatment system based on federated learning, which has the following characteristics: a federated model is obtained by the following method: step S1, initializing the server and each client; step S2, each client is connected to the server; step S3, the local data is preprocessed; step S4, the server constructs a federated global model, and then sends the federated global model to each client connected to the server; step S5, each client respectively trains the federated global model according to the preprocessed data, and sends the obtained learning data to the server; step S6, the server updates the federated global model according to all the learning data, and then sends the updated federated global model to each client; step S7, steps S5 to S6 are repeatedly executed until the training is completed, and the federated model is obtained. In short, the method can improve the segmentation accuracy.

This application provides a method for constructing an MSMP-SAM image encoder based on multi-pooling feature adaptive extraction, relating to the field of general image data processing technology. It processes images through image analysis and region segmentation. This application constructs a multi-pooling feature adaptive extraction module (MSMP), where multi-scale feature extraction can simultaneously cover diffuse large-area lesions and small local lesions in diabetic retinopathy (DR), effectively solving the problem of significant scale differences in DR lesions. Multi-pooling can take into account the detailed texture and global structural information of different types of lesions, improving the segmentation completeness and localization accuracy of diverse lesions. Through the collaborative design of multi-pooling and multi-scale, this application fundamentally improves the model's feature perception and segmentation capabilities for DR, significantly enhancing segmentation accuracy in medical imaging scenarios and further strengthening the model's clinical adaptability and practical value.

Provided herein are methods of treating various eye disorders, including, for example, wet age-related macular degeneration (wAMD) or diabetic retinopathy (DR), using an anti-VEGF therapy, such as an anti-VEGF antibody conjugate.

This invention discloses an early screening and intelligent follow-up management system and method for diabetic retinopathy (DR), belonging to the field of artificial intelligence in medicine and primary care chronic disease management. The system consists of a fundus image acquisition terminal, a lightweight DR AI diagnostic module, a multimodal physiological monitoring unit, an intelligent follow-up and early warning engine, a hierarchical diagnosis and treatment scheduling platform, and a cloud-edge collaborative server. The DR AI diagnostic module is built based on EfficientNetV2-B0, with a file size ≤15MB after INT8 quantization and a single-image inference time ≤50ms, allowing it to run offline on mobile phones and tablets. After training on 10386 labeled fundus images, it achieves an accuracy of 93.7%, an AUC of 0.952, and a sensitivity of 91.3%, effectively identifying early lesions. The system connects to devices such as blood glucose meters and blood pressure monitors to achieve real-time monitoring of physiological indicators, pushing early warnings within 10 seconds of abnormalities, improving follow-up compliance, and establishing a closed loop of "primary screening at the grassroots level—higher-level diagnosis and treatment—community follow-up," thereby improving the efficiency of primary care chronic disease screening and management.

The present application relates to methods of treating ocular diseases. In particular, the present application provides the use of a combination therapy of administering a thymidylate synthetase inhibitor and a vascular endothelial growth factor inhibitor and a monotherapy of administering capecitabine in ocular diseases. The diseases have one or more of the following characteristics: ocular vascular leakage, ocular vascular pathology, retinal fibrosis, scarring, and retinal inflammation. Representative diseases include neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.

The invention relates to the technical field of medical instruments, in particular to a diabetic retinopathy examination device which comprises a liftable seat, a backrest is hinged to the top of the seat, an examination table is hinged to the side, close to the seat, of the backrest, and a pitching adjusting mechanism used for adjusting the angle of the examination table is arranged on the backrest; the examining table is fixedly connected with a chin support and a forehead cushion; the side, away from the backrest, of the inspection table is fixedly connected with a guide shaft, and an optical cabin is slidably matched in the guide shaft. The device further comprises a first linkage mechanism, a second linkage mechanism and a third linkage mechanism. The first linkage mechanism is used for driving the pitching adjusting mechanism to make pitching motion in the backrest adjusting process, so that the height of the forehead cushion is matched with the eyebrow position of the sitting patient. According to the invention, errors possibly occurring during manual adjustment can be further reduced, the alignment precision of inspection is improved, and the imaging quality fluctuation caused by the difference of operation techniques is reduced.

The application discloses a panax notoginseng saponins ophthalmic gel preparation and a preparation method and application thereof. The panax notoginseng saponins ophthalmic gel preparation comprises panax notoginseng saponins, EDTA-2Na, a gel matrix carbomer 980, mannitol, a preservative, a pH regulator, water for injection and the like. Through optimization and screening of each component and content, the panax notoginseng saponins ophthalmic gel preparation can deliver the drug into the eye for multiple times, improve the bioavailability of the eye, and improve the pharmacodynamic effect of preventing and treating diseases such as diabetic retinopathy and diabetic cataract, and has good clinical applicability and drug property.

A method for performing retinal volumetric measurements based on the Early Treatment for Diabetic Retinopathy Study (ETDRS) grid is presented. The method includes receiving an optical coherence tomography (OCT) image of a retina of a patient and ETDRS mapping information identifying one or more subfields of the ETDRS grid and segmenting the OCT image of the retina to identify one or more layer features corresponding to layers of the retina and one or more disease-associated features associated with the one or more layer features. The method further includes determining, based on the segmented OCT image, one or more volumetric measurements of the one or more disease-associated features. The one or more volumetric measurements correspond to the ETDRS mapping information. The method further includes generating a report based on the one or more volumetric measurements.